Purchase Order 75N93020P01113

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for COVID-19 reagents with a ceiling value of $26,145.00, effective April 9, 2021. Performance is located in San Diego, California, with an ultimate completion date of May 7, 2021. The order is firm fixed price with no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed-price purchase order valued at $21,863.25 to Biolegend, Inc. for BIOLEGEND TOTALSEQ ANTIBODIES. No set-aside designation was used. Performance will occur in San Diego, California with a completion date of May 7, 2024. Biolegend, Inc. is a subsidiary of Revvity Inc.'s Medical Imaging, LLC division. The award is likely associated with research efforts...

This firm-fixed-price federal purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical products. The $31,957.50 contract supports the supply of various antibodies, reagents, and kits to advance research initiatives across NIAID, with no set-aside designation. Biolegend has a long history of providing specialized products for...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $14,023.75 on July 22, 2020, for Brilliant Violet anti-human CD8A RPA-T8 and Brilliant Violet anti-human CD154 antibody clone 24-31 reagents to support COVID-19 research. Performance occurs in San Diego, California, with completion targeted for August 21, 2020. The order is firm fixed-price with no small business set-aside.</p>

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a $56,762.00 firm-fixed-price purchase order to Biolegend, Inc. for the supply of various biological research products, including Alexa Fluor 700 anti-human IFN-γ and several Brilliant Violet-labeled antibodies for human cellular markers. This acquisition was processed under Simplified Acquisition Procedures without a small business set-aside. Biolegend, a...

This purchase order, awarded to Biolegend, Inc. on September 17, 2021, represents an administrative action by the National Institute of Allergy and Infectious Diseases (NIAID) to de-obligate $10,568 in unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a). The contract, which was ultimately completed on October 17, 2021, is structured as a firm fixed-price purchase order with no small business set-aside designation. The place of performance is located in...

This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Illumina, Inc. for $14,688.00 for an Illumina reagent kit, with an award date of August 12, 2020 and completion date of September 11, 2020. The order is firm fixed price with no set-aside. Place of performance is San Diego, California.</p>